Dendritic Cell Antigen Loading via Permeable Peptides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dendritic cell therapy for cancer treatment has limited success due to low immunogenicity of tumor cells and immunosuppressive substances secreted by cancer cells, which hampers the induction of effective anti-cancer immunity.
Innovation Solution
A method involving the maturation of dendritic cells in the presence of a maturation factor, followed by sensitization with an antigen bound to a cell membrane-permeable peptide, enhancing the cells' cytotoxic T lymphocyte induction ability and antigen-presenting capacity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If dendritic cells are sensitized with antigen at immature stage, then antigen uptake ability is improved, but cytotoxic T lymphocyte induction ability is insufficient
Solution Approach 1:
The patent applies preliminary action by first sensitizing the dendritic cells with antigen at the immature stage to ensure adequate antigen uptake, then maturing the cells before injecting them back into the patient. This sequential approach allows the cells to accumulate sufficient antigen while developing the maturity needed for effective T cell induction, resolving the contradiction between antigen uptake and CTL induction capability
Solution Approach 2:
The patent employs dynamics by transitioning dendritic cells from an immature state (optimized for antigen uptake) to a mature state (optimized for T cell activation) through controlled maturation processes. This dynamic state change allows the same cell population to sequentially perform different functions: first antigen capture, then immune activation, thereby resolving the functional trade-off
2Reliability
If dendritic cells are matured before antigen sensitization, then cytotoxic T lymphocyte induction ability is improved, but antigen-presenting ability is reduced
Solution Approach 1:
The patent performs antigen sensitization as a preliminary action before maturation, ensuring that dendritic cells have sufficient antigen loaded when they are still in the immature state with high antigen uptake capacity. After this preliminary antigen loading, the cells are then matured to gain T cell activation capability, thus preserving both antigen-presenting ability and CTL induction ability
3Ease of manufacture
If conventional dendritic cell therapy is used, then treatment is simpler, but therapeutic effect is limited due to low immunogenicity of tumor cells
Solution Approach 1:
The patent creates a composite therapeutic approach by combining dendritic cells with tumor antigens in a specific sequence (sensitization followed by maturation), effectively creating a composite immune stimulus that overcomes the low immunogenicity of tumor cells. This composite strategy maintains relative treatment simplicity while dramatically improving therapeutic effect through the synergistic combination of antigen-loaded mature dendritic cells
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly improves the migration ability, IL-12 secretion, T cell proliferation, and cytotoxic T lymphocyte induction, leading to enhanced anti-tumor immune responses and therapeutic effects.
Implementation Method 1
an antigen bound to a peptide having a cell membrane permeability
Data Source
Figure 1a~1b
Figure 1c~1d
Figure 2a~2b
AI summary
The present invention relates to a method for preparing a dendritic cell, a dendritic cell prepared thereby and a use thereof, and more specifically, to a method for preparing a dendritic cell, including: treating a dendritic cell at a maturation stage rather than at an immature stage with an antigen bound to a peptide having a cell membrane permeability to prepare a dendritic cell with improved antigen-presenting ability, a dendritic cell prepared by the method, and an immunotherapeutic agent thereof, a use for anti-tumor vaccines, or a pharmaceutical composition for treating tumors, containing the same.